RELAPSING REMITTING MULTIPLE SCLEROSIS

This study tested an experimental oral medication called PIPE-307 in 182 adults with relapsing-remitting multiple sclerosis (MS). Participants took either a low dose, high dose, or a placebo pill alongside their usual MS treatment for about 30 weeks. The main goals were to check …

This study looked at the safety of Kesimpta, a drug for multiple sclerosis (MS), in 367 people with relapsing-remitting MS or active secondary progressive MS. Researchers tracked side effects and how doctors rated symptom changes. The goal was to monitor real-world use, not to te…

This study looked at whether a multiple sclerosis drug called ofatumumab (Kesimpta) can make immune cells less damaging to brain cells. Researchers took blood samples from 40 people with relapsing-remitting MS before and after 6 months of treatment. They tested if the substances …

This study looked at how the first wave of COVID-19 (April–June 2020) changed the way people with multiple sclerosis reported relapses and how doctors managed them, compared to the same months in 2019. Researchers reviewed records from 51 patients across 5 UK hospitals to see if …

This study looked at 58 people to see if those with an unusual form of multiple sclerosis (MS) have different levels of nerve damage markers in their blood compared to people with classic MS and healthy controls. The goal was to better understand if these atypical cases are a sep…

This study looked at whether virtual reality (VR) tasks, like driving or shopping in a virtual store, can better detect attention and planning problems in people with relapsing-remitting multiple sclerosis (MS) compared to standard paper-and-pencil tests. Sixty adults with MS and…

This study tested a special eye-imaging technique called adaptive optics to look at blood vessel changes in the retina of people with multiple sclerosis (MS). Researchers measured swelling around retinal vessels in 50 participants with different MS types and compared them to heal…